Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and announces Price Target of $8.